Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross antipsychotics coverage update |…
    Ask Trek AI about this page
    CurrentPremera BluecrossPolicy 5.01.659

    Antipsychotics — Second‑generation antipsychotic pharmacy coverage

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.659 alerts

    Get alerted when Policy 5.01.659 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Pharmacy policy defining medical necessity criteria, prior authorization requirements, age and quantity limits, and documentation expectations for oral second‑generation antipsychotic products managed under the pharmacy benefit.

    Policy Summary
    PayerPremera Bluecross
    PolicyAntipsychotics — Second‑generation antipsychotic pharmacy coverage
    Policy CodePolicy 5.01.659
    Change TypeMaterial updates to product-specific criteria and quantity limits
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with documentation of prior generic SGA trials and required medical records; approvals may be issued up to 12 months when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage criteria for Bysanti (milsaperidone).

    Updated criteria for Cobenfy (xanomeline and trospium chloride) to add a quantity limit of 60 capsules per 30 days.

    Removed brand clozapine and brand clozapine ODT from the policy as they are no longer on the market.

    12 monthsmaximum approval duration
    60Cobenfy quantity limit
    24 mg/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Bysanti dose limit
    ≥18minimum age

    Coverage Criteria

    Brand SGA and product‑specific medical necessity

    Brand second‑generation antipsychotics are considered medically necessary when product‑specific trial and other criteria are met.

    General brand SGA requirement: For most brand SGAs the individual must have tried 1 generic second‑generation antipsychotic and had an inadequate response or intolerance (applies to individuals not previously treated with the requested therapy).1 generic SGA trial

    See individual drug entries for exceptions requiring more trials

    Bysanti (milsaperidone): Individual is aged 18 years or older AND has tried 2 generic second‑generation antipsychotics and had an inadequate response or intolerance AND the dose is limited to 24 mg daily.age >=18; 2 generic SGA trials; dose <=24 mg/day

    Product‑specific requirement

    Cobenfy (xanomeline and trospium chloride): Individual is aged 18 years or older AND has been diagnosed with schizophrenia per DSM criteria AND has tried 3 generic second‑generation antipsychotics and had an inadequate response or intolerance AND prescribed by or in consultation with a psychiatrist AND the dose is limited to 125 mg/30 mg capsule twice daily AND the quantity is limited to 60 capsules per 30 days.age >=18; 3 generic SGA trials; dose and quantity limits specified

    Product‑specific requirement

    Opipza (aripiprazole oral film): Either the individual has tried 1 generic second‑generation antipsychotic and had an inadequate response or intolerance OR documentation is provided that the oral film formulation is clinically necessary (e.g., trouble swallowing); the dose is limited to 30 mg per day.1 generic SGA trial OR clinical necessity for formulation; dose <=30 mg/day

    Product‑specific alternative pathway

    Rexulti (brexpiprazole): Individual has tried aripiprazole and had an inadequate response or intolerance. For agitation associated with dementia due to Alzheimer's disease, documentation of agitation is required and the dose is limited to 3 mg once daily.trial of aripiprazole; dose <=3 mg/day for AD agitation

    Product‑specific requirement and boxed warning regarding dementia‑related psychosis

    Vraylar (cariprazine) for bipolar depression: Individual is aged 18 years or older AND has been diagnosed with bipolar depression AND has tried quetiapine, lurasidone, or olanzapine‑fluoxetine combination and had an inadequate response or intolerance.age >=18; trial of specified agents

    Product‑specific requirement

    Latuda (lurasidone HCL) for bipolar depression: Individual has tried generic lurasidone and had an inadequate response or intolerance prior to brand Latuda coverage.trial of generic lurasidone

    Product‑specific requirement

    Nuplazid (pimavanserin): Coverage is limited to treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Nuplazid is not subject to the other brand SGA criteria in this policy.Parkinson's disease psychosis indication

    Product restricted to PD psychosis

    Use of drugs for conditions not listed in this policy is considered investigational. This policy applies the product‑specific medical necessity criteria and FDA‑approved indications for the antipsychotic agents included; therapies or indications not described here are not covered under these criteria.

    Use of medications that do not meet the product‑specific criteria in this policy or that are prescribed for indications not listed in this policy are considered investigational and not medically necessary. Coverage decisions require documentation that the request meets the listed drug‑specific requirements (for example, required prior trials, age limits, dose and quantity limits) or evidence of clinical justification as specified in the individual drug entries.

    Provider Actions and Requirements

    Prior Authorization

    Obtain prior authorization; approvals up to 12 months

    Prior authorization is required for brand second‑generation antipsychotics. When criteria are met, approvals may be issued for up to 12 months.

    Step Therapy

    Document required trials of generic SGAs (1–3 trials depending on product)

    Most brand SGAs require documented prior trials of generic second‑generation antipsychotics; the number of required trials varies by product (typically 1, and for some products 2 or 3).

    • General requirement: 1 generic SGA trial with inadequate response or intolerance for individuals not previously treated with the requested therapy ([[see citations]]).
    • Bysanti (milsaperidone): requires trial of 2 generic SGAs and age ≥18; dose limit 24 mg/day.
    • Cobenfy (xanomeline and trospium chloride): requires trial of 3 generic SGAs and age ≥18; additional product‑specific requirements apply.

    Initial Therapy

    Initial therapy — product-specific initial approval rules

    Initial approval rules vary by product.

    General: Initial authorization may be approved up to 12 months when drug‑specific coverage criteria are met.12 months

    Reauthorization / Continuation Criteria

    Reauthorization

    Reauthorization

    Reauthorization criteria: May be approved up to 12 months when drug‑specific coverage criteria are met and chart notes demonstrate continued positive clinical response to therapy.documentation of ongoing benefit

    Step Therapy Requirements

    ProductRequired number of prior generic SGA trials
    {"text":"Abilify (aripiprazole)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Brand quetiapine / Seroquel / Seroquel XR","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Caplyta (lumateperone)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Fanapt (iloperidone)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Geodon (ziprasidone) oral","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Invega (paliperidone)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Latuda (lurasidone) [brand]","status":""}|{"text":"Requires trial of generic lurasidone (i.e., 1 generic SGA trial of lurasidone) prior to brand coverage","status":""}
    {"text":"Lybalvi (olanzapine and samidorphan)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Risperdal (risperidone)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Saphris / Secuado (asenapine formulations)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Vraylar (cariprazine)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance); product-specific requirements for bipolar depression require trials of quetiapine, lurasidone, or olanzapine‑fluoxetine combination","status":""}
    {"text":"Zyprexa / Zyprexa Zydis (olanzapine)","status":""}|{"text":"1 generic SGA trial (documentation of inadequate response or intolerance)","status":""}
    {"text":"Bysanti (milsaperidone)","status":""}|{"text":"2 generic SGA trials (documentation of inadequate response or intolerance); individual must be aged ≥18 and dose limited to 24 mg/day","status":""}
    {"text":"Cobenfy (xanomeline and trospium chloride)","status":""}|{"text":"3 generic SGA trials (documentation of inadequate response or intolerance); individual must be aged ≥18 and meet schizophrenia diagnosis and psychiatrist involvement","status":""}
    {"text":"Nuplazid (pimavanserin)","status":""}|{"text":"Not subject to the other brand SGA trial requirements; restricted to Parkinson's disease psychosis indication","status":""}
    {"text":"Opipza (aripiprazole oral film)","status":""}|{"text":"Either 1 generic SGA trial OR documentation that oral film formulation is clinically necessary (e.g., trouble swallowing)","status":""}
    {"text":"Rexulti (brexpiprazole)","status":""}|{"text":"Requires trial of aripiprazole (specified generic SGA) with inadequate response or intolerance","status":""}
    {"text":"Symbyax (fluoxetine‑olanzapine)","status":""}|{"text":"Requires trial of generic fluoxetine‑olanzapine with inadequate response or intolerance","status":""}

    Product-Specific Quantity and Dose Limits

    Cobenfy (xanomeline and trospium chloride) — quantity limit
    Quantity limit60 capsules per 30 days
    Dose form and strength125 mg/30 mg capsule, twice daily dosing specified in product criteria
    Age requirementIndividual must be aged 18 years or older
    Bysanti (milsaperidone) — dose limit
    Dose limit24 mg per day
    Age requirementIndividual must be aged 18 years or older
    Step therapy requirementMust have tried 2 generic second‑generation antipsychotics and had inadequate response or intolerance

    Coding Information

    Site of Care

    Note

    Manage oral SGAs through the pharmacy benefit

    These oral antipsychotic drugs are managed through the pharmacy benefit; submit requests and prescriptions via pharmacy channels per benefit rules.

    Definitions

    First‑generation antipsychotics (FGAs)
    DefinitionAlso called typical antipsychotics; original drugs for psychosis with higher risk of movement-related side effects such as extrapyramidal symptoms (EPS) and tardive dyskinesia.
    Clinical roleUsed to treat acute psychosis and chronic psychotic disorders; associated with higher risk of EPS than second-generation antipsychotics.
    Policy contextDistinguished from second-generation antipsychotics; policy focuses on criteria for second-generation agents.
    Second‑generation antipsychotics (SGAs)
    DefinitionAlso called atypical antipsychotics; generally lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia compared to FGAs.
    Coverage focusPolicy defines when brand second-generation antipsychotics may be considered medically necessary with product-specific trial and other criteria.

    Background

    Antipsychotic medications are used to treat acute psychosis and chronic psychotic disorders such as schizophrenia, and are also used for acute agitation and bipolar mania. First‑generation antipsychotics are associated with a higher risk of extrapyramidal symptoms and tardive dyskinesia, whereas second‑generation (atypical) antipsychotics generally have a lower risk of these movement‑related adverse effects. This policy establishes when brand second‑generation antipsychotics are considered medically necessary based on product‑specific criteria, including required prior trials of generic SGAs, age and dose/quantity limits, and indication‑specific restrictions.

    Policy Summary
    PayerPremera Bluecross
    PolicyAntipsychotics — Second‑generation antipsychotic pharmacy coverage
    Policy CodePolicy 5.01.659
    Change TypeMaterial updates to product-specific criteria and quantity limits
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with documentation of prior generic SGA trials and required medical records; approvals may be issued up to 12 months when criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and RequirementsInitial TherapyReauthorization / Continuation CriteriaStep Therapy RequirementsProduct-Specific Quantity and Dose LimitsCoding InformationSite of CareDefinitionsBackground
    Documentation Required

    Provide complete medical record documentation with request

    Submit office visit notes that document the diagnosis, relevant history, physical evaluation, and medication history to demonstrate that medical necessity criteria are met.

    • Include documentation of inadequate response or intolerance to required generic SGA trials as applicable per product‑specific criteria.
    • For product‑specific approvals, include supporting documentation required by the drug entry (e.g., DSM diagnosis for Cobenfy; clinical necessity for Opipza formulation).
    Denial Risk

    Denial risk if required prior trials are not documented

    Requests may be denied if records do not document the required number of prior generic SGA trials and inadequate response or intolerance as specified in the product‑specific criteria.

    • Failure to document the required trials (e.g., 1 general trial, 2 for Bysanti, 3 for Cobenfy) and associated outcomes risks denial of the request.
    Opipza (aripiprazole oral film) — dose/limit (30 mg)
    Dose limit30 mg per day
    Step therapy or alternative pathwayRequires trial of 1 generic second‑generation antipsychotic and inadequate response or intolerance OR documentation that oral film formulation is clinically necessary (e.g., trouble swallowing)
    Benefit applicationManaged under pharmacy benefit as oral medication
    Rexulti (brexpiprazole) for agitation in dementia due to Alzheimer's disease — dose/limit (3 mg)
    Dose limit (agitation in dementia due to Alzheimer’s disease)3 mg once daily
    Indication-specific requirementDocumentation required that individual has agitation associated with dementia due to Alzheimer’s disease (examples: pacing, gesturing, profanity, shouting, shoving, hitting)
    Safety noteRexulti is not approved for dementia-related psychosis without agitation (boxed warning)
    Common generic examplesAripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone (used as comparator generic SGAs in step requirements)